Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as a sterile injection for intravenous administration. It is employed in the treatment of metastatic colorectal cancer and other advanced solid tumours in adult oncology patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, clinics and pharmacies worldwide, supporting oncology therapy across diverse health systems and research institutions.

Irinotecan is a topoisomerase I inhibitor used in specific oncologic indications. - Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens. - Advanced gastric cancer: may be employed in combination therapy for refractory disease. - Advanced pancreatic cancer: used as part of combination regimens in selected patients.

Irinotecan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: may be severe and require prompt management. - Nausea and vomiting: common during and after infusion. - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis or intestinal perforation: life‑threatening bowel complications. - Hypersensitivity reactions: including anaphylaxis, rash, or bronchospasm.

When using Irinotecan Accord, clinicians should observe several safety measures to minimize risk. - Dose adjustment: consider hepatic or renal impairment before dosing. - Monitor blood counts: perform regular CBC to detect neutropenia early. - Assess for diarrhea: initiate antidiarrheal therapy at first sign. - Avoid strong CYP3A4 inhibitors: may increase exposure to SN‑38. - Pregnancy: use only if potential benefit justifies potential risk to fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise SN‑38 levels and toxicity. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: immunosuppression may lead to infection.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness. - Other myelosuppressive agents (e.g., carboplatin): additive bone‑marrow suppression. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea.